Cargando...
Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
Epidermal growth factor receptor tyrosine kinase inhibitors, gefitnib and erlotinib, are effective for advanced nonsmall-cell lung cancer with epidermal growth factor receptor gene mutation. However, interstitial lung disease induced by these drugs is sometimes fatal, and discontinuation of the medi...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Blackwell Publishing Ltd
2013
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4184641/ https://ncbi.nlm.nih.gov/pubmed/25473530 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.12 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|